A Phase 1 interventional study of ERX-315 in Advanced Solid Tumor, Metastatic Breast Cancer and Metastatic Ovarian Cancer, sponsored by EtiraRx Australia Pty Ltd. Recruiting at 5 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by EtiraRx Australia Pty Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.
The goal of this open-label, dose escalation and cohort expansion Phase 1 clinical trial is to determine the safety, tolerability and pharmacokinetics of ERX-315 in patients with advanced solid tumors, who have progressed on prior approved systemic therapies. Participants will receive ERX-315 as an intravenous (IV) injection twice a week, over 21-day cycles.
This is the only study on the registry with EtiraRx Australia Pty Ltd as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active investigational therapy
Drug: ERX-315
Drug administered intravenously twice a week at increasing dose levels, with starting dose of 0.4mg/kg.
Incidence of Dose Limiting Toxicities of ERX-315
First cycle dose limiting toxicities characterized by type, frequency, severity, timing, seriousness, and relationship to study drug
Time frame: 21 days
Incidence of Adverse Events as a measure of safety and tolerability of ERX-315
Adverse events as characterized by type, frequency, severity (grade), timing, seriousness, and relationship to study drug.
Time frame: 84 days
Incidence of laboratory abnormalities as a measure of safety and tolerability of ERX-315
Laboratory abnormalities as characterized by type, frequency, severity, and timing.
Time frame: 84 days
Determination of the recommended phase 2 dose
To determine the recommended phase 2 dose(s) for additional evaluation of ERX-315 in clinical trials for participants with advanced solid tumors
Time frame: 84 days
Assessment of pharmacokinetic outcome measure of Area under the plasma concentration versus time curve (AUC).
AUC will be determined by non-compartmental analysis and assessed after single and multiple doses of drug
Time frame: 21 days
Assessment of pharmacokinetic outcome measure of Peak Plasma concentration (Cmax)
Cmax will be determined by non-compartmental analysis and assessed after single and multiple doses of drug
Time frame: 21 days
Assessment of pharmacokinetic outcome measure of drug half-life (t1/2)
t1/2 will be assessed after single and multiple doses of drug
Time frame: 21 days
Antitumor activity of ERX-315 based on Objective response rate (ORR)
ORR will be assessed by RECIST v1.1
Time frame: 84 days
Antitumor activity of ERX-315 based on Best Overall Clinical Response (BOCR)
BOCR will be assessed by RECIST v1.1
Time frame: 84 days
Antitumor activity of ERX-315 based on Duration of response (DOR)
DOR will be assessed by RECIST v1.1 and time frame of response
Time frame: 84 days
Antitumor activity of ERX-315 based on Progression-free survival (PFS)
PFS will be assessed by RECIST v1.1 and time frame of response
Time frame: 84 days
Impact on patient reported symptoms using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire
Effect of ERX-315 on the changes from baseline in patient reported symptoms using the PRO-CTCAE Questionnaire
Time frame: 84 days
Serum LIPA lipase activity as pharmacodynamic markers of ERX-315 activity
The effect of ERX-315 on serum LIPA lipase activity may be evaluated
Time frame: 84 days
Circulating tumor DNA levels as pharmacodynamic markers of ERX-315 activity
The effect of ERX-315 on circulating tumor DNA levels may be evaluated
Time frame: 84 days
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.